Pfizer pulls PAH drug Thelin from market after unpredictable deaths

Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.

Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.

While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapeutic Category

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.